<DOC>
	<DOCNO>NCT02658292</DOCNO>
	<brief_summary>A Double-Blind , Randomized , Vehicle-Controlled , Multicenter Study Evaluate Efficacy Safety NAFT-900 Children Aged 6 &lt; 13 Years Tinea Capitis</brief_summary>
	<brief_title>Safety Efficacy NAFT900 Children With Tinea Capitis</brief_title>
	<detailed_description>This 8-week double-blind , randomize , vehicle-controlled , multicenter study NAFT-900 compare vehicle treatment tinea capitis child ≥6 year &lt; 13 year age . There approximately 60 subject enrol . Qualifying subject clinical evidence tinea capitis infection involve ≤ 15 % scalp , confirm positive culture , randomize 2:1 one follow treatment : - NAFT-900 ( Naftifine hydrochloride foam , 3 % ) - Vehicle Foam The study consist 6 visit . Subjects apply assign study product twice daily affected area ( ) 4 week</detailed_description>
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Capitis</mesh_term>
	<mesh_term>Naftifine</mesh_term>
	<criteria>1 . Subjects clinical diagnosis tinea capitis ≤15 % involvement scalp . 2 . Subjects positive KOH microscopy culture [ dermatophytes ] . 3 . Male female subject ≥6 year &lt; 13 year age date Baseline Visit . 1 . Subject acute inflammatory fungal infection scalp ( kerion ) 2 . Subjects skin disease scalp , condition prior/present treatment opinion investigator would interfere study drug 's effect assessment ( e.g. , psoriasis , seborrheic dermatitis ) . 3 . Subjects receive immunosuppressant therapy , cytostatic therapy radiation therapy within 4 week prior baseline . 4 . Subjects receive systemic corticosteroid and/or systemic antibiotic within 4 week prior study entry ( study ) . 5 . Subjects use systemic antifungal treatment within 4 week prior baseline . 6 . Subjects used antifungal agent , corticosteroid preparation , ketoconazole , ciclopirox , salicylic acid , terbinafine , amorolfine , butenafine , clotrimazole , econazole , oxiconazole , sertaconazole , sulconazole , luliconazole , fluconazole , benzoic acid , griseofulvin , undecylenic acid , zinc pyrithione selenium sulfide , tar contain topical treatment scalp within 1 week prior baseline visit . 7 . Subjects lifethreatening condition ( ex . autoimmune deficiency syndrome , cancer , unstable angina , myocardial infarction ) within last 6 month prior baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>fungus</keyword>
	<keyword>antifungal</keyword>
	<keyword>skin infection</keyword>
	<keyword>hair infection</keyword>
	<keyword>dermatophyte</keyword>
	<keyword>scalp</keyword>
	<keyword>skin</keyword>
	<keyword>eyebrow</keyword>
	<keyword>eyelash</keyword>
	<keyword>hair</keyword>
	<keyword>Trichophyton</keyword>
	<keyword>Microsporum</keyword>
	<keyword>Endothrix</keyword>
	<keyword>spore</keyword>
</DOC>